News

FDA Targets Firms Marketing Sham Diabetes Products on the Internet


 

The sale of products that are misrepresented as cures or treatments for diabetes and the Internet sites that advertise these products are the target of a campaign launched by U.S., Mexican, and Canadian government agencies.

The Food and Drug Administration and the Federal Trade Commission (FTC) announced in a statement that the FDA had issued 24 warning letters to companies marketing dietary supplements with claims that the products treated, cured, prevented, or mitigated diabetes. To date, about 180 letters and other advisories have been sent to online outlets in the three countries as a result of the campaign.

The FTC also announced a new campaign aimed at educating consumers about how to avoid falling for sham diabetes cures. Included is an example of a Web site promoting a phony product called Glucobate.

“The Internet can be a great source of information, but it also is a billboard for ads that promise miracle cures for diabetes and other serious diseases,” Lynda Parnes, director of the FTC's Bureau of Consumer Protection, said in the statement.

“We will not tolerate practices that raise false hopes and bilk consumers of precious health care dollars,” Margaret O'K. Glavin, the FDA's associate commissioner for regulatory affairs, said in the statement.

An example of one warning letter, sent by the FDA to a Reno, Nev.-based company about its product called “Enhansulin,” notes that the product is advertised as containing extract from “Caucasian blueberry leaves.” The letter says that marketing this product with the therapeutic claims that appear on its Web site establishes it as a drug and, therefore, violates the Federal Food, Drug, and Cosmetic Act. Among the claims on the Web site, according to the letter, is the statement that Caucasian blueberry leaves have been “effectively used to manage the effects of diabetes” for centuries.

The list of the 24 companies that have been sent warning letters, with links to the letters, is on the FDA's Web site at http://www.cfsan.fda.gov/∼dms/dialist.htmlhttp://wemarket4u.net/glucobate/index.html

Recommended Reading

Not All Thyroid Cancer Patients Need Follow-Up
MDedge Family Medicine
More Thyroid Tumors Being Found in Women
MDedge Family Medicine
Think Androgen Excess in Women With Hirsutism
MDedge Family Medicine
Race, Gender Complicate Heart Disease, BMD Link
MDedge Family Medicine
Sequential Tx Sustains Benefits Of Teriparatide in Osteoporosis
MDedge Family Medicine
Periodic Ibandronate Injections Improve Bone Density at 2 Years
MDedge Family Medicine
Ibandronate Shots Better in Those With GI Intolerance
MDedge Family Medicine
FDA Approves Sitagliptin for Glycemic Control
MDedge Family Medicine
On-Site Educators Lead to Better Type 2 Outcomes
MDedge Family Medicine
Sleep-Disordered Breathing Tied to Hyperglycemia in Type 2
MDedge Family Medicine